237 related articles for article (PubMed ID: 17632867)
1. [Negative would be welcome. The question is whose brain child this is].
Hakimi R
MMW Fortschr Med; 2006 Nov; 148(44):8. PubMed ID: 17632867
[No Abstract] [Full Text] [Related]
2. [Legal dispute about the black drug list. Irrespective of positive or negative list--I am in favor].
Thöns M
MMW Fortschr Med; 2006 Oct; 148(40):8. PubMed ID: 17338085
[No Abstract] [Full Text] [Related]
3. [Drug guidelines. Put on hold for the next 4 years. Interview by Peter Jentsch].
Bausch J
MMW Fortschr Med; 1999 Aug; 141(33):51-2. PubMed ID: 10766543
[No Abstract] [Full Text] [Related]
4. [New institute for additional drug evaluation. Do we really need another barrier?].
Schmidt K
MMW Fortschr Med; 2003 Jul; 145(29-30):55-6. PubMed ID: 12958781
[No Abstract] [Full Text] [Related]
5. Bill 102: deal or no deal for big pharma.
Rasky H
Health Law Can; 2007 May; 27(4):73-84. PubMed ID: 17580795
[No Abstract] [Full Text] [Related]
6. [Thorough clarification of national health insurance statistics. This prevents regress actions].
Thomas A
MMW Fortschr Med; 2007 Nov; 149(48):56-7. PubMed ID: 18163264
[No Abstract] [Full Text] [Related]
7. [Limited prescribing freedom by federal cost regulation?].
Lasek R
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):633-5. PubMed ID: 9527458
[TBL] [Abstract][Full Text] [Related]
8. [Medication prices in Germany--how are they determined?].
Bruhn C
Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
[No Abstract] [Full Text] [Related]
9. [New drugs must henceforth be better than the current standard. What remains for physician therapy autonomy?].
Schmidt K
MMW Fortschr Med; 2006 Dec; 148(49-50):61, 63. PubMed ID: 17619334
[No Abstract] [Full Text] [Related]
10. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany].
Pruszydlo MG; Quinzler R; Kaltschmidt J; Haefeli WE
Dtsch Med Wochenschr; 2008 Jul; 133(27):1423-8. PubMed ID: 18592450
[TBL] [Abstract][Full Text] [Related]
11. [Does red-green destroy phytotherapy?].
Krankenpfl J; 2003; 41(4-6):111. PubMed ID: 12929322
[No Abstract] [Full Text] [Related]
12. [The physician caught between two chairs. Comments on the difficulty in dealing with off-label use].
Harder Yv
Urologe A; 2007 Oct; 46(10):1429-34. PubMed ID: 17786403
[No Abstract] [Full Text] [Related]
13. [Pharmacists want to assume penalty].
MMW Fortschr Med; 2006 May; 148(20):55. PubMed ID: 16805194
[No Abstract] [Full Text] [Related]
14. [European court. Drug budgets of physicians remain reduced].
MMW Fortschr Med; 2004 Mar; 146(13):57. PubMed ID: 15219133
[No Abstract] [Full Text] [Related]
15. [Regulation for improving economics in drug treatment].
Holstein L; Koch B
Chirurg; 2006 Jul; Suppl():214-6. PubMed ID: 17855869
[No Abstract] [Full Text] [Related]
16. [Only what happens in your own practice counts. No fear of collective regress].
Schmidt KA
MMW Fortschr Med; 2000 Nov; 142(44):47. PubMed ID: 11107807
[No Abstract] [Full Text] [Related]
17. [Sequlae of "silent rationing". Substantial deficits in drug management].
MMW Fortschr Med; 2001 Jan; 143(4):43. PubMed ID: 11219284
[No Abstract] [Full Text] [Related]
18. [GMG proposal for non-prescription medications. Expensive cost savings].
MMW Fortschr Med; 2004 Aug; 146(31-32):48. PubMed ID: 15529713
[No Abstract] [Full Text] [Related]
19. [Vascular specialists in a campaign against positive list. Threat of deficient care for 4.5 million vascular patients].
Krankenpfl J; 2003; 41(4-6):120. PubMed ID: 12929329
[No Abstract] [Full Text] [Related]
20. Changes to the Pharmaceutical Benefits Advisory Committee.
Henry DA; Birkett DJ
Med J Aust; 2001 Mar; 174(5):209-10. PubMed ID: 11280687
[No Abstract] [Full Text] [Related]
[Next] [New Search]
